New Blood Test Predicts Kidney Failure Risk For Black Americans Decades Before Disease Onset

University of Pennsylvania researchers develop a blood test identifying kidney failure risk in Black Americans years before symptoms appear.

By: AXL Media

Published: Apr 15, 2026, 7:30 AM EDT

Source: Information for this report was sourced from EurekAlert!

Early Detection Through Proteomic Mapping

A breakthrough study published in Nature Medicine has introduced a diagnostic blood test that identifies early disease activity in individuals of African ancestry carrying APOL1 gene variants. While roughly five million Americans carry these high-risk genetic markers, a majority never develop chronic conditions, making early identification difficult for clinicians. Senior author Katalin Susztak, a professor at the Perelman School of Medicine, explained that the new approach captures biological shifts before standard clinical measures can detect a loss of function. This diagnostic window allows for earlier intervention, potentially preventing the transition from a genetic predisposition to a life-threatening medical emergency.

Identifying Extreme Risk Disparities

The research team analyzed blood samples from over 850 participants in the Penn Medicine BioBank who exhibited normal kidney function at the start of the study. By measuring a specific panel of circulating proteins, the researchers developed a risk score to forecast outcomes over the following decade. The findings revealed a staggering disparity between risk groups: over 60% of those in the highest-risk category suffered renal failure requiring dialysis or transplantation within ten years. In stark contrast, fewer than 1% of participants in the lowest-risk group experienced similar outcomes, demonstrating the test’s high precision in separating those with benign genetic variants from those facing imminent organ failure.

Capturing Pre-Clinical Tissue Injury

The proteins utilized in the risk score are closely associated with biological pathways involved in kidney fibrosis and cellular injury. By monitoring these specific markers, the test acts as a direct readout of early tissue damage that precedes the measurable decline of kidney filtration rates. According to the research team, this methodology shifts the focus of risk assessment away from reactive clinical monitoring and toward a proactive understanding of disease biology. Because these markers reflect active injury at the tissue level, they provide a more accurate picture of a patient's trajectory than current diagnostic tools, which often only flag issues after significant and permanent damage has occurred.